143 related articles for article (PubMed ID: 1701585)
1. Development and evaluation of an enzyme-linked immunoassay for the prostate: specific antigen utilizing two monoclonal antibodies.
Zundel D; Jarry H; Kestler D; Holzapfel G; Bartels H; Scheit KH; Wuttke W
Urol Res; 1990; 18(5):327-30. PubMed ID: 1701585
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
3. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen in prostatic cancer.
Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A
Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279
[TBL] [Abstract][Full Text] [Related]
5. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
Saedi MS; Hill TM; Kuus-Reichel K; Kumar A; Payne J; Mikolajczyk SD; Wolfert RL; Rittenhouse HG
Clin Chem; 1998 Oct; 44(10):2115-9. PubMed ID: 9761243
[TBL] [Abstract][Full Text] [Related]
6. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
Armitage TG; Cooper EH; Newling DW; Robinson MR; Appleyard I
Br J Urol; 1988 Dec; 62(6):584-9. PubMed ID: 2464397
[TBL] [Abstract][Full Text] [Related]
7. New ultrasensitive assay development by using monoclonal antibodies for detecting prostate-specific antigen.
Di Silverio F; D'Eramo G; Flammia GP; Caponera M; Macrí D; Loreto A; Sciarra A
Eur Urol; 1992; 21 Suppl 1():79-82. PubMed ID: 1385136
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.
Chan DW; Bruzek DJ; Oesterling JE; Rock RC; Walsh PC
Clin Chem; 1987 Oct; 33(10):1916-20. PubMed ID: 2444361
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker.
Leitenberger A; Altwein JE
Eur Urol; 1990; 17(1):12-6. PubMed ID: 1690653
[TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
Buamah PK; Johnson P; Skillen AW
Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen.
Jurincic-Winkler C; von der Kammer H; Horlbeck R; Klippel KF; Pixberg HU; Scheit KH
Eur Urol; 1993; 24(4):487-91. PubMed ID: 7507048
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
[TBL] [Abstract][Full Text] [Related]
16. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study.
Morote Robles J; Ruibal Morell A; Palou Redorta J; de Torres Mateos JA; Soler Roselló A
Eur Urol; 1988; 14(5):360-6. PubMed ID: 2458936
[TBL] [Abstract][Full Text] [Related]
17. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
18. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
[TBL] [Abstract][Full Text] [Related]
19. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
[TBL] [Abstract][Full Text] [Related]
20. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
